Aesica, a pharmaceutical company based in the North West of England is planning to double its production capability as a result of a recent acquisition of three European manufacturing sites. The acquisition of the leading biopharma company UCB by the Newcastle-based Aesica, will mark the pharmaceutical company’s first expansion outside the UK. It also demonstrates the firm’s commitment to enhance its service offering to the global pharmaceutical and biotechnology industries. Aesica chief executive Dr Robert Hardy said: “To have secured manufacturing sites in Europe and on such a large scale is testament to our commitment to ensuring Aesica is recognised as a leading player on the world stage. “It was vital that we capitalised on recent successes, such as the acquisition of R5 earlier this year, which has significantly enhanced our development and formulations capability, and ensured that the momentum was carried forward as we looked to acquire assets in Europe, which we believe will be a key market for us in 2011.” Are you looking for a new position in the UK Pharmaceutical Industry? Click here to search our current pharmaceutical jobs online now.